Kinathera Overview
- Year Founded
-
2015
- Status
-
Out of Business
- Employees
-
5
- Latest Deal Type
-
Liquidation
Kinathera General Information
Description
Operator of a pharmaceutical company intended to bring a pharmacological therapeutic approach for the treatment of immunofibrotic autoimmune diseases. The company develops oral chemical entities specific for the inhibition of TBK1/IKKe in rare immuno-fibrotic diseases such as scleroderma or lupus nephritis, with animal proof of concept in therapeutic mode on pulmonary fibrosis and modulation of Type I interferon and autoantibodies, enabling physicians to improve human quality of life.
Contact Information
Website
www.kinathera.comCorporate Office
- 163 avenue de Luminy, Luminy Biotech Entreprises
- Bâtiment Béret-Delaage, Case 922
- 13288 Marseille
- France
Corporate Office
- 163 avenue de Luminy, Luminy Biotech Entreprises
- Bâtiment Béret-Delaage, Case 922
- 13288 Marseille
- France
Kinathera Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 10. Bankruptcy: Liquidation | 03-Apr-2024 | Completed | Bankruptcy: Liquidation | |||
| 9. Seed Round | 09-Aug-2023 | Completed | Pre-Clinical Trials | |||
| 8. Accelerator/Incubator | 01-Aug-2022 | Completed | Pre-Clinical Trials | |||
| 7. Secondary Transaction - Private | Completed | Pre-Clinical Trials | ||||
| 6. Seed Round | 13-Jun-2022 | Completed | Pre-Clinical Trials | |||
| 5. Seed Round | 22-Dec-2017 | Completed | Pre-Clinical Trials | |||
| 4. Angel (individual) | Completed | Startup | ||||
| 3. Grant | Completed | Startup | ||||
| 2. Accelerator/Incubator | Completed | Startup | ||||
| 1. Accelerator/Incubator | Completed | Startup |
Kinathera Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Ordinary Shares |
Kinathera Patents
Kinathera Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| FR-3095755-A1 | New cytoprotective drugs | Inactive | 10-May-2019 | ||
| WO-2020229761-A1 | Novel cytoprotective medicaments | Inactive | 10-May-2019 | ||
| US-11458189-B2 | Cytoprotective drugs | Inactive | 17-Nov-2017 | ||
| FR-3073738-A1 | New cytoprotective medicines | Inactive | 17-Nov-2017 | ||
| AU-2018366352-A1 | Novel cytoprotective drugs | Inactive | 17-Nov-2017 | A61K38/12 |
Kinathera Signals
Kinathera FAQs
-
When was Kinathera founded?
Kinathera was founded in 2015.
-
Where is Kinathera headquartered?
Kinathera is headquartered in Marseille, France.
-
What is the size of Kinathera?
Kinathera has 5 total employees.
-
What industry is Kinathera in?
Kinathera’s primary industry is Biotechnology.
-
Is Kinathera a private or public company?
Kinathera is a Private company.
-
What is Kinathera’s current revenue?
The current revenue for Kinathera is .
-
How much funding has Kinathera raised over time?
Kinathera has raised $29.5M.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process